Insmed Inc. to Share Fourth-Quarter and Full-Year 2025 Financial Results
Bridgewater, NJ – February 5, 2026 – Insmed Incorporated (Nasdaq: INSM), a prominent biopharmaceutical company dedicated to improving the lives of patients with serious diseases, is set to release its financial results for the fourth quarter and full year of 2025. The press release comes as anticipation builds for insights into the company’s performance and future outlook.
1. Conference Call Scheduled for February 19, 2026
Insmed will host a conference call on Thursday, February 19, 2026, starting at 8:00 a.m. ET. This call will be a platform for the company’s management to discuss the financial outcomes for the year and provide a comprehensive update on business developments.
Participation Details
Interested parties, including shareholders and analysts, can join the call by dialing:
- U.S.: (888) 210-2654
- International: (646) 960-0278
Participants are advised to reference access code 7862189 to ensure smooth entry into the call. Additionally, the event will be webcast live on the company's official website, allowing broader access for those unable to attend via phone.
2. Replay and Webcast Options
For those who wish to revisit the discussion, a replay of the conference call will be available approximately one hour after its conclusion. The replay can be accessed until February 26, 2026, using the following numbers:
- U.S.: (800) 770-2030
- International: (609) 800-9909
Listeners should reference the same access code 7862189. Furthermore, the webcast will be archived for 90 days in the Investor Relations section of Insmed’s website.
3. About Insmed Incorporated
Insmed is committed to being a people-first global biopharmaceutical company, focusing on delivering first- and best-in-class therapies to address serious health conditions. The company boasts a diverse portfolio, which includes both approved and investigational medicines targeting pulmonary and inflammatory diseases. Notably, Insmed has developed two therapies specifically designed to treat chronic lung diseases, showcasing its commitment to critical areas of patient need.
The company is also advancing its early-stage programs, which leverage innovative technologies including gene therapy, AI-driven protein engineering, and synthetic rescue. This strategic focus on cutting-edge drug discovery positions Insmed as a leader in addressing complex medical challenges.
Headquartered in Bridgewater, New Jersey, Insmed maintains a strong presence across the U.S., Europe, and Japan, furthering its mission to transform the lives of patients worldwide. The company has garnered recognition as a top employer in the biopharmaceutical industry, achieving the title of No. 1 Science Top Employer for five consecutive years.
For further information, stakeholders can visit Insmed's website or follow the company on various social media platforms including LinkedIn, Instagram, YouTube, and X.
As the date approaches, market watchers and investors will be eager to glean insights from Insmed’s performance, which may provide important indicators of the company’s trajectory in the biopharmaceutical landscape.
